Welcome to our dedicated page for Hutchmed (China) news (Ticker: HCM), a resource for investors and traders seeking the latest updates and insights on Hutchmed (China) stock.
HUTCHMED (China) Limited (HCM) news covers the company’s ongoing work as a commercial-stage biopharmaceutical developer of targeted therapies and immunotherapies for cancer and immunological diseases. Press releases frequently describe progress across its in-house pipeline, regulatory milestones in China and abroad, and updates on marketed medicines such as ELUNATE® (fruquintinib), ORPATHYS® (savolitinib) and SULANDA® (surufatinib).
Investors and healthcare professionals following HUTCHMED news can expect detailed reports on clinical trial results, including Phase II and Phase III data in solid tumors and autoimmune hematologic diseases. Recent announcements have highlighted Phase III outcomes for savolitinib plus TAGRISSO® in EGFR-mutated non-small cell lung cancer, topline Phase III results for sovleplenib in warm antibody autoimmune hemolytic anemia, and initiation or expansion of studies such as the Phase II/III trial of surufatinib and camrelizumab in metastatic pancreatic ductal adenocarcinoma.
News items also address regulatory and reimbursement developments, such as New Drug Application acceptances with priority review for savolitinib in MET-amplified gastric cancer and fanregratinib in intrahepatic cholangiocarcinoma, as well as inclusion of HUTCHMED-associated medicines on China’s National Reimbursement Drug List and the National Commercial Health Insurance Innovative Drug List. These updates provide context on how the company’s therapies may reach broader patient populations.
Another recurring theme is platform and pipeline strategy, including announcements about the ATTC (Antibody-Targeted Therapy Conjugate) platform and first-in-human trials of HMPL-A251, as well as presentations at major scientific meetings such as ESMO, ASH and AACR-NCI-EORTC. For those tracking HCM, this news feed offers a centralized view of clinical data readouts, partnership activities, regulatory interactions and broader R&D progress. Bookmarking this page allows readers to follow how HUTCHMED’s oncology and immunology programs evolve over time.
HUTCHMED and Epizyme announced a collaboration to develop TAZVERIK® in Greater China. Epizyme will receive an upfront payment of $25 million, potential milestones of up to $285 million, and tiered royalties. HUTCHMED gains development and commercial rights in China. TAZVERIK®, an EZH2 inhibitor FDA-approved for certain cancers, aims to accelerate clinical trials in various malignancies. HUTCHMED plans to lead trials in combination with other therapies and commercialize the drug upon approval.
Epizyme and HUTCHMED announced a collaboration to develop and commercialize TAZVERIK® in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan. TAZVERIK® is an FDA-approved EZH2 methyltransferase inhibitor for certain patients with epithelioid sarcoma and follicular lymphoma. Epizyme will receive a $25 million upfront payment, with potential milestone payments of up to $285 million, plus royalties. HUTCHMED will lead clinical trials and commercialization in the region, aiming to expand TAZVERIK®'s reach and potential applications.
HUTCHMED reported significant growth in its interim financial results for H1 2021, with total revenues up by 47% to $157.4 million. Sales for ELUNATE® surged 186% to $40.1 million, while SULANDA® generated $8.0 million since its January launch. The company received its first approval in China for ORPATHYS® and accepted applications for surufatinib in the U.S. and E.U. HUTCHMED raised $615 million through an additional listing on HKEX, bolstering its cash resources to approximately $1.2 billion.
HUTCHMED and AstraZeneca have launched a Phase II study of ORPATHYS® (savolitinib) for treating advanced MET amplified gastric cancer. The trial, initiated on July 27, 2021, aims to assess efficacy, safety, and pharmacokinetics with a focus on objective response rate (ORR). This follows the successful VIKTORY trial, which reported a 50% ORR. MET amplification is found in 4-6% of gastric cancer patients, with about 24,000 cases annually in China. ORPATHYS® is already marketed in China for non-small cell lung cancer with specific MET alterations.
HUTCHMED (HCM) announced the end of the stabilization period for its Global Offering on July 23, 2021. Morgan Stanley Asia Limited acted as the Stabilizing Manager, undertaking stabilizing actions that included over-allocations of 15,600,000 Offer Shares, representing about 15% of the total Offer Shares. Additionally, these shares were borrowed to cover over-allocations. The Over-allotment Option was fully exercised on July 12, 2021. No market purchases were made for price stabilization during this period. For detailed information, refer to the company’s announcement from July 12, 2021.
The European Medicines Agency (EMA) has accepted HUTCHMED's marketing authorization application for surufatinib, aimed at treating neuroendocrine tumors (NETs). This follows recent FDA NDA acceptance in the U.S. for the same indication. Surufatinib offers a dual mechanism to inhibit tumor growth by targeting specific receptors. Positive results from two Phase III studies in China support the application, indicating a growing potential market as the drug is already launched in China.
HUTCHMED announces the first commercial sale of ORPATHYS® (savolitinib) in China, which occurred on July 12, 2021. This follows the June 22, 2021 approval for treating non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping alterations. A milestone payment of $25 million from AstraZeneca is triggered by this sale. ORPATHYS® targets a critical mutation affecting 2-3% of NSCLC patients, with a notable prevalence in aggressive subtypes. The drug's efficacy is supported by robust clinical trial data, showing a 42.9% objective response rate.
HUTCHMED (HCM) announced the full exercise of the over-allotment option in its Global Offering, resulting in the issuance of 15,600,000 shares at HK$40.10 each. This increases total issued shares to 864,115,660, with CK Hutchison Holdings now holding 38.48% of voting rights. The gross proceeds are approximately HK$625 million, earmarked for existing projects. Listing on the Hong Kong Stock Exchange is set for July 15, 2021, with AIM admission at the London Stock Exchange expected on July 16, 2021.
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) has initiated a Phase I study for HMPL-295, an oral ERK inhibitor targeting the RAS-MAPK pathway. The trial started on July 2, 2021, assessing HMPL-295's safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced malignant tumors. This study aims to establish the maximum tolerated dose and recommended Phase II dose. HUTCHMED retains all rights to HMPL-295 worldwide, marking a significant step in addressing resistance in cancer therapies.
HUTCHMED (HCM) will announce its interim results for the six months ending June 30, 2021, on July 28, 2021, at 12:00 noon BST. Analysts and investors are invited to participate in a conference call at 1:00 pm BST, which will be live-streamed on the company's website. As a biopharmaceutical company focused on cancer and immunological disease therapies, HUTCHMED has advanced multiple drug candidates into clinical studies, with three oncology drugs already approved. More details will be provided in the financial results announcement.